Shares of RPG Life Sciences Ltd fell 5.82% to ₹2,346.90 in early trade on Monday after the company posted a marginal decline in net profit for the quarter ended June 2025. The stock opened weak and quickly hit a low of ₹2,400.10, sharply down from the previous close of ₹2,491.80.
The RPG Group company reported a profit after tax (PAT) of ₹26.29 crore in Q1 FY26, compared to ₹26.76 crore in the same quarter last year. Revenue from operations, however, rose 2% year-on-year to ₹168.92 crore, up from ₹165.42 crore in Q1 FY25.
Managing Director Ashok Nair stated that the company maintained its sales growth momentum during the quarter, driven by its domestic formulations segment. He highlighted strategic initiatives, customer focus, and operational execution as key pillars for growth.
RPG Life Sciences also reiterated its focus on international formulations and API segments, backed by rapid customer onboarding, new market entry, and the launch of innovative molecules. The company is also actively exploring inorganic growth opportunities to strengthen its portfolio.
Despite a relatively stable operating performance, investor sentiment appeared dampened by the slight decline in profit, triggering the near 6% sell-off.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.